Edgewise Therapeutics, Inc.
US ˙ NasdaqGS ˙ US28036F1057

SecurityEWTX / Edgewise Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership2,246,028 shares
Latest Disclosed Value $ 70,749,883
Morgan Stanley reports 22.84% decrease in ownership of EWTX / Edgewise Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 2,246,028 shares of Edgewise Therapeutics, Inc. (US:EWTX) valued at $70,749,882 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 2,910,881 shares of Edgewise Therapeutics, Inc.. This represents a change in shares of -22.84% during the quarter. The current value of the position is $83,619,622 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 2,246,028 -664,853 -22.84 70,750 -2.05 0.0043
2026-05-27 2025-12-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 2,910,881 2,041,203 234.71 72,234 412.07 0.0043
2026-02-13 2025-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 2,910,881 2,041,203 72,234 0.0043
2026-05-27 2025-09-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 869,678 141,964 19.51 14,106 47.86 0.0009
2025-11-14 2025-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 869,678 141,964 14,106 0.0009
2025-08-15 2025-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 727,714 318,717 77.93 9,540 6.04 0.0006
2025-05-15 2025-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 408,997 -27,433 -6.29 8,998 -22.79 0.0006
2025-05-15 2024-12-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 436,430 18,299 4.38 11,653 4.42 0.0008
2025-02-14 2024-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 436,430 18,299 11,653 0.0008
2025-05-14 2024-09-30 13F/A-2 EDGEWISE THERAPEUTICS COM 28036F105 418,131 168,157 67.27 11,160 147.87 0.0008
2025-02-14 2024-09-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 418,131 168,157 11,160 0.0008
2024-11-14 2024-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 418,131 168,157 11,160 0.0001
2025-05-14 2024-06-30 13F/A-2 EDGEWISE THERAPEUTICS COM 28036F105 249,974 -124,744 -33.29 4,502 -34.12 0.0003
2024-10-17 2024-06-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 249,974 -124,744 4,502 0.0003
2024-08-14 2024-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 249,974 -124,744 4,502 0.0003
2024-10-17 2024-03-31 13F/A-2 EDGEWISE THERAPEUTICS COM 28036F105 374,718 149,539 66.41 6,835 177.47 0.0005
2024-08-16 2024-03-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 374,718 149,539 6,835 0.0001
2024-05-15 2024-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 374,718 149,539 6,835 0.0005
2024-08-16 2023-12-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 225,179 152,108 208.16 2,463 489.23 0.0002
2024-02-13 2023-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 225,179 152,108 2,463 0.0002
2023-11-15 2023-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 73,071 -27,322 -27.22 419 -46.27 0.0000
2023-08-14 2023-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 100,393 36,120 56.20 778 81.78 0.0001
2023-05-15 2023-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 64,273 3,972 6.59 429 -20.59 0.0000
2023-02-14 2022-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 60,301 -44,436 -42.43 539 -47.72 0.0001
2022-11-14 2022-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 104,737 57,773 123.02 1,031 175.67 0.0001
2022-10-27 2022-06-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 46,964 24,989 113.72 374 74.77 0.0000
2022-08-15 2022-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 46,964 24,989 374 0.0000
2022-10-27 2022-03-31 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 21,975 4,798 27.93 214 -18.32 0.0000
2022-05-13 2022-03-31 13F EDGEWISE THERAPEUTICS COM 28036F105 21,975 4,798 214 0.0000
2022-02-14 2021-12-31 13F EDGEWISE THERAPEUTICS COM 28036F105 17,177 16,311 1,883.49 262 1,771.43 0.0000
2021-11-15 2021-09-30 13F EDGEWISE THERAPEUTICS COM 28036F105 866 404 87.45 14 40.00 0.0000
2021-08-23 2021-06-30 13F/A-1 EDGEWISE THERAPEUTICS COM 28036F105 462 462 10 0.0000
2021-08-16 2021-06-30 13F EDGEWISE THERAPEUTICS COM 28036F105 462 462 10 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.